Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8122789 | 1.00 | KDM4E (0.37) | KDM4EMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3731792 | 0.82 | KDM4E (0.38) | KDM4EMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5522727 | 0.82 | MEN1 (0.40) | KDM4EMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8627478 | 0.82 | KDM4E (0.38) | KDM4EMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11298974 | 0.82 | MEN1 (0.40) | KDM4EMAPTCYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL9827792 | 0.79 | KDM4E (0.36) | KDM4EMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13957832 | 0.77 | PTGS1 (0.45) | KDM4EMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL19061572 | 0.77 | KDM4E (0.45) | KDM4EMAPTCYP3A4CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL11597040 | 0.75 | PTGS1 (0.44) | KDM4EMAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL12317978 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
| US-5395931-A | 6-amido-1-methyl-2-(substituted-thio)carbapenems | MERCK & CO., INC. (US) | 1995-03-07 | — | — | US | disclosed |
| US-4182863-A | ANTIBACTERIAL | BRISTOL-MYERS COMPANY (US) | 1980-01-08 | — | — | US | disclosed |
| US-4171438-A | 0-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
| US-4151352-A | CEPHALOSPORINS, BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4118566-A | Δ2,3 -1,4-Morpholine-2-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4100346-A | Certain 7(o-amino-methyl- or methylaminomethylphenyl- or cyclohexadienyl- or thienylacetamide)-3[1-carboxymethyl-(or ethyl- or propyl-)-tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acids | BRISTOL-MYERS COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4082912-A | ANTIBACTERIAL | BRISTOL-MYERS COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4068066-A | ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-4065622-A | O-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4013648-A | BETA-LACTAM ANTIBIOTICS | BRISTOL-MYERS COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3946000-A | BACTERICIDES, POULTRY, ANIMALS | BRISTOL-MYERS COMPANY (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | KDM4E 2715/4885MAPT 4482/4885CYP3A4 313/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | KDM4E 4093/4885MAPT 3289/4885CYP3A4 134/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | KDM4E 2715/4885MAPT 4482/4885CYP3A4 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.